ArticleInfectious diseases of poverty2026
First imported case of New World leishmaniasis in Romania: diagnostic and therapeutic challenges in a non-endemic country.
Article in Infectious diseases of poverty, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis is a vector-borne protozoan disease with cutaneous, mucocutaneous, and visceral forms. In Europe, most cases involve Old World species, while imported New World infections are rare. We report the first imported human case of New World cutaneous leishmaniasis in Romania. CASE PRESENTATION: A 25-year-old woman developed progressive ulcerative lesions on her left arm after travel to Panama and Costa Rica. Initial biopsy revealed granulomatous inflammation without identifying the agent. A second biopsy detected amastigotes within macrophages, and molecular analyses (ITS1 sequencing, hsp70 phylogenetic analysis) identified Leishmania panamensis. The patient received oral miltefosine for 28 days, with gradual improvement and complete healing with atrophic scars. No relapse occurred 473 days post-treatment.
conclusionsThis case highlights diagnostic challenges in non-endemic regions, emphasizing the need to raise clinical awareness and improve access to molecular tools for prompt recognition and management of imported leishmaniasis in Eastern Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.